Palvella Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Palvella Therapeutics, Inc. (PVLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $0.85 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2024-03-29
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2017-09-30 was $3.34, a 218.10% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2017-06-30 was $2.08, a 90.83% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2017-03-31 was $1.31, a 31.00% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2016-09-30 was $1.05, a 46.15% decline year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $0.85, a 56.63% decline from fiscal 2022.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $1.96, a 3.92% decline from fiscal 2021.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $2.04, a 6.25% increase from fiscal 2020.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2020 was $1.92.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.85 10-K · filed 2024-03-29 | |||
| 2022-12-31 | $1.96 10-K · filed 2024-03-29 | |||
| 2021-12-31 | $2.04 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $1.92 10-K · filed 2022-03-02 | |||
| 2017-09-30 | $3.34 10-Q · filed 2017-11-13 | $2.02 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | $2.08 10-Q · filed 2017-08-11 | $1.39 10-Q · filed 2017-08-11 | ||
| 2017-03-31 | $1.31 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $1.00 10-K · filed 2017-03-30 | |||
| 2016-09-30 | $1.05 10-Q · filed 2017-11-13 | $1.01 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | $1.09 10-Q · filed 2017-08-11 | $1.01 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | $1.00 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | $1.87 10-K · filed 2017-03-30 | |||
| 2015-09-30 | $1.95 10-Q · filed 2016-11-10 | $1.94 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $1.81 10-Q · filed 2016-08-11 | $1.82 10-Q · filed 2016-08-11 | ||
| 2015-03-31 | $1.86 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |